DexCom, Inc. (NASDAQ:DXCM) Holdings Cut by Reynders McVeigh Capital Management LLC

Reynders McVeigh Capital Management LLC reduced its stake in shares of DexCom, Inc. (NASDAQ:DXCM – Get Rating) by 4.5% during the 3rd quarter, HoldingsChannel reports. The fund owned 25,188 shares of the medical device company’s stock after selling 1,200 shares during the period. Reynders McVeigh Capital Management LLC’s holdings in DexCom were worth $2,029,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the stock. Crewe Advisors LLC bought a new position in DexCom during the second quarter valued at approximately $26,000. Sound Income Strategies LLC increased its stake in shares of DexCom by 300.0% during the 3rd quarter. Sound Income Strategies LLC now owns 320 shares of the medical device company’s stock worth $26,000 after purchasing an additional 240 shares during the last quarter. Bivin & Associates Inc. raised its holdings in shares of DexCom by 300.0% during the 2nd quarter. Bivin & Associates Inc. now owns 360 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 270 shares in the last quarter. Ronald Blue Trust Inc. lifted its stake in shares of DexCom by 860.5% in the 3rd quarter. Ronald Blue Trust Inc. now owns 365 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 327 shares during the last quarter. Finally, Private Trust Co. NA bought a new stake in DexCom in the second quarter worth $29,000. 94.01% of the stock is owned by institutional investors and hedge funds.

DexCom Price Performance

Shares of NASDAQ:DXCM traded up $1.25 during midday trading on Thursday, reaching $108.96. 298,541 shares of the company’s stock were exchanged, compared to its average volume of 2,441,416. The company has a debt-to-equity ratio of 1.08, a quick ratio of 3.43 and a current ratio of 3.77. The company’s 50 day simple moving average is $112.05 and its two-hundred day simple moving average is $100.41. DexCom, Inc. has a 12 month low of $66.89 and a 12 month high of $134.76. The firm has a market capitalization of $42.09 billion, a PE ratio of 198.55, a price-to-earnings-growth ratio of 2.93 and a beta of 1.11.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on DXCM shares. StockNews.com upgraded DexCom from a “hold” rating to a “buy” rating in a report on Friday, January 27th. Cowen boosted their target price on DexCom from $85.00 to $114.00 in a report on Friday, October 28th. BTIG Research increased their price target on DexCom to $126.00 in a report on Tuesday, November 1st. Raymond James boosted their price objective on shares of DexCom from $101.00 to $125.00 and gave the stock an “outperform” rating in a research note on Friday, October 28th. Finally, Wells Fargo & Company upped their price objective on shares of DexCom from $102.00 to $128.00 and gave the stock an “overweight” rating in a report on Friday, October 28th. Two investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, DexCom currently has a consensus rating of “Moderate Buy” and a consensus target price of $121.94.

Insiders Place Their Bets

In other news, CFO Jereme M. Sylvain sold 2,400 shares of the company’s stock in a transaction that occurred on Monday, November 21st. The stock was sold at an average price of $112.62, for a total value of $270,288.00. Following the sale, the chief financial officer now directly owns 67,237 shares in the company, valued at approximately $7,572,230.94. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other DexCom news, CFO Jereme M. Sylvain sold 2,400 shares of the company’s stock in a transaction on Monday, November 21st. The stock was sold at an average price of $112.62, for a total value of $270,288.00. Following the sale, the chief financial officer now directly owns 67,237 shares in the company, valued at $7,572,230.94. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Paul R. Flynn sold 8,988 shares of DexCom stock in a transaction on Thursday, December 8th. The shares were sold at an average price of $123.50, for a total value of $1,110,018.00. Following the transaction, the executive vice president now directly owns 55,744 shares of the company’s stock, valued at $6,884,384. The disclosure for this sale can be found here. Insiders sold a total of 116,876 shares of company stock worth $12,562,898 over the last quarter. Company insiders own 0.41% of the company’s stock.

DexCom Company Profile

(Get Rating)

DexCom, Inc is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F.